ACADIA Pharmaceuticals Inc.
ACAD
Rang in aandelen
#4461
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Aandeelprijs
$20.27
Marktkapitalisatie
$3.49B
Verandering (1 dag)
2.35%
Verandering (1 jaar)
-3.22%
Land
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Categorie
Healthcare
Winst voor ACADIA Pharmaceuticals Inc. (ACAD)
Winst in Jun 2026 TTM: $121.37M
Volgens de meest recente financiële verslagen van ACADIA Pharmaceuticals Inc. bedraagt de huidige winst van het bedrijf $121.37M. In 2023 behaalde het bedrijf een winst van $-51.04M, een stijging ten opzichte van de winst van 2022, die $-213.44M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van ACADIA Pharmaceuticals Inc. van 2000 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $121.37M | -52.97% |
| 2024 | $258.08M | -605.67% |
| 2023 | $-51.04M | -76.09% |
| 2022 | $-213.44M | 27.41% |
| 2021 | $-167.52M | -40.38% |
| 2020 | $-280.97M | 19.88% |
| 2019 | $-234.38M | -3.92% |
| 2018 | $-243.94M | -15.38% |
| 2017 | $-288.28M | 6.75% |
| 2016 | $-270.05M | 64.55% |
| 2015 | $-164.11M | 77.47% |
| 2014 | $-92.48M | 143.69% |
| 2013 | $-37.95M | 82.01% |
| 2012 | $-20.85M | -8.42% |
| 2011 | $-22.77M | -250.37% |
| 2010 | $15.14M | -133.53% |
| 2009 | $-45.15M | -29.73% |
| 2008 | $-64.24M | 13.93% |
| 2007 | $-56.39M | 25.18% |
| 2006 | $-45.05M | 31.97% |
| 2005 | $-34.14M | 31.71% |
| 2004 | $-25.92M | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | 4,246.20% |
US
|
|
| $-3.09B | -2,643.50% |
US
|
|
| $-4.02B | -3,409.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,507.22% |
NL
|
